Twist Bioscience (TWST) revenue and earnings history
Twist Bioscience reported revenue of $459M for fiscal 2026 (year ended Sep 30, 2026), +22.0% on the year before, and net income of −$130M.
Over 9 years, from fiscal 2017 to fiscal 2026, revenue grew at a compound rate of +51.7% a year.
Revenue and net income, 10 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026ended Sep 30, 2026 | $459M+22.0% | −$139M | −$130M | −$41.4M | $47.6M | −$89M | $69.9M | — | — | $534M | — | 10-K |
| 2025ended Sep 30, 2025 |
The latest quarter, insider trades and fund moves: Twist Bioscience (TWST) on OQRO.
Common questions
What was Twist Bioscience's revenue in fiscal 2026?
$459M for the year ended Sep 30, 2026, as reported in its 10-K filed Nov 16, 2026. That is +22.0% on fiscal 2025 ($377M).
How fast has Twist Bioscience's revenue grown?
From $10.8M in fiscal 2017 to $459M in fiscal 2026: a compound annual growth rate of +51.7% over 9 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Twist Bioscience been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Twist Bioscience tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
